Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis ...

Some patients with atopic dermatitis who qualify for advanced systemic therapies do not receive them or may lack improvement with these therapies.

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Discover expert-relief solutions for managing atopic dermatitis, from breakthrough treatments to daily habits that prevent ...

Medically reviewed by Katlein Franca, MD Atopic dermatitis is a chronic (long-lasting) skin condition that causes dry, itchy ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

ATOPIC dermatitis (AD) is the most common chronic inflammatory skin condition, affecting up to 10% of adults and up to 20% of ...

Dupilumab treatment of atopic dermatitis resulted in long-term skin improvements linked to changes in skin’s the molecular composition.

PFIZER, a global biopharmaceutical company, today announced the availability of Cibinqo (abrocitinib) and Staquis (crisaborole) as new additions to the atopic dermatitis treatment spectrum in Malaysia ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 SYX-5219 is a ...